With today's focus on targeted and minimally invasive therapies, photodynamic therapy (PDT) is now being studied and used to combat many disease states and to investigate critical biological questions. This groundbreaking resource brings practitioners and researchers the latest advances in photodynamic therapy and offers a solid understanding of the design, delivery and dosimetry of the three basic ingredients of PDT - photosensitizers, light and oxygen. The book covers novel areas of mechanistic and innovative translational approaches. Moreover, it presents an overview of the important medical applications of PDT, including approved treatments, clinical trials, and investigated therapies for cancer and non-malignant diseases.
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
Michael R. Hamblin is a principal investigator at the Wellman Center for Photomedicine at Massachusetts General Hospital and an associate professor of dermatology at Harvard Medical School. He was trained as a synthetic organic chemist and received his Ph.D. from Trent University in England. He has published over 85 peer-reviewed articles, over 150 conference proceedings, book chapters and International abstracts and holds 8 patents. Pawel Mroz is a research fellow at the Wellman Center for Photomedicine, Massachusetts General Hospital. Dr. Mroz is currently conducting research in the area of Photodynamic therapy (PDT) - a new, cutting-edge approach for treating cancers and other diseases. Dr. Mroz is a graduate of the Medical University of Warsaw, Poland.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.